Tuesday, July 28, 2026

Patent directory · USPTO A61K / A61P

Browse patents

Browse 1,585 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 1,585
Companies 800
Drugs linked 4,222

Quick answer

NovaPharmaNews indexes 1,585 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code — or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 4 of 67
  1. US 12290566

    Dosing regimens and related compositions and methods

    Apellis Pharmaceuticals, Inc. · Granted May 6, 2025 · Expires May 1, 2045

    granted
  2. US 12285417

    Methods for treating chronic obstructive pulmonary disease

    Theravance Biopharma R&D IP, LLC · Granted Apr 29, 2025 · Expires Apr 24, 2045

    granted
  3. US 12285419

    Bupivacaine multivesicular liposome formulations and uses thereof

    Pacira Pharmaceuticals, Inc. · Granted Apr 29, 2025 · Expires Apr 24, 2045

    granted
  4. US 12281113

    Crystalline forms of a KRas G12C inhibitor

    Mirati Therapeutics, Inc. · Granted Apr 22, 2025 · Expires Apr 17, 2045

    granted
  5. US 12280037

    Method and pharmaceutical composition for treating or preventing trichomoniasis and uses thereof

    EVOFEM BIOSCIENCES, INC. · Granted Apr 22, 2025 · Expires Apr 17, 2045

    granted
  6. US 12280093

    Use of a VEGF receptor-based fusion protein antagonist to treat nonproliferative diabetic retinopathy

    REGENERON PHARMACEUTICALS, INC. · Granted Apr 22, 2025 · Expires Apr 17, 2045

    granted
  7. US 12280149

    Manufacturing of bupivacaine multivesicular liposomes

    Pacira Pharmaceuticals, Inc. · Granted Apr 22, 2025 · Expires Apr 17, 2045

    granted
  8. US 2025120959

    NEW FORMULATIONS OF PITOLISANT AND METHODS OF USE

    BIOPROJET PHARMA [FR] · Granted Apr 17, 2025 · Expires Apr 12, 2045

    granted
  9. US 12274696

    Methods of administering nalbuphine

    Trevi Therapeutics, Inc. · Granted Apr 15, 2025 · Expires Apr 10, 2045

    granted
  10. US 12268730

    Use of a VEGF antagonist to treat angiogenic eye disorders

    REGENERON PHARMACEUTICALS, INC. · Granted Apr 8, 2025 · Expires Apr 3, 2045

    granted
  11. US 12268695

    Betulin-containing birch bark extracts and their formulation

    Amryt Pharmaceuticals Designated Activity Company · Granted Apr 8, 2025 · Expires Apr 3, 2045

    granted
  12. US 12263139

    Use of cannabidiol in the treatment of tuberous sclerosis complex

    JAZZ PHARMACEUTICALS RESEARCH UK LIMITED · Granted Apr 1, 2025 · Expires Mar 27, 2045

    granted
  13. US 12263148

    Levodopa dosing regimen

    AMNEAL PHARMACEUTICALS LLC · Granted Apr 1, 2025 · Expires Mar 27, 2045

    granted
  14. US 12263145

    Methods of administering solriamfetol to lactating women

    AXSOME MALTA LTD. · Granted Apr 1, 2025 · Expires Mar 27, 2045

    granted
  15. US 12263149

    Levodopa dosing regimen

    AMNEAL PHARMACEUTICALS LLC · Granted Apr 1, 2025 · Expires Mar 27, 2045

    granted
  16. US 12257242

    Inhibition of crystal growth of roflumilast

    ARCUTIS BIOTHERAPEUTICS, INC. · Granted Mar 25, 2025 · Expires Mar 20, 2045

    granted
  17. US 12257224

    Methods of administration for highly water-soluble salts of a short acting phenylalkylamine calcium channel blocker

    Milestone Pharmaceuticals Inc. · Granted Mar 25, 2025 · Expires Mar 20, 2045

    granted
  18. US 12251468

    Manufacturing of bupivacaine multivesicular liposomes

    Pacira Pharmaceuticals, Inc. · Granted Mar 18, 2025 · Expires Mar 13, 2045

    granted
  19. US 12251472

    Manufacturing of bupivacaine multivesicular liposomes

    Pacira Pharmaceuticals, Inc. · Granted Mar 18, 2025 · Expires Mar 13, 2045

    granted
  20. US 12246092

    Manufacturing of bupivacaine multivesicular liposomes

    Pacira Pharmaceuticals, Inc. · Granted Mar 11, 2025 · Expires Mar 6, 2045

    granted
  21. US 12246023

    Use of reboxetine to treat narcolepsy

    AXSOME THERAPEUTICS, INC. · Granted Mar 11, 2025 · Expires Mar 6, 2045

    granted
  22. US 12246064

    Method of treating Crohn's disease by administering a triple combination therapy of anti-integrin antibody, adalimumab and methotrexate

    Takeda Pharmaceutical Company Limited · Granted Mar 11, 2025 · Expires Mar 6, 2045

    granted
  23. US 12233106

    C-type natriuretic peptide variants to treat skeletal dysplasia in children

    BIOMARIN PHARMACEUTICAL INC. · Granted Feb 25, 2025 · Expires Feb 20, 2045

    granted
  24. US 12233166

    Extended release compositions comprising pyridostigmine

    Amneal Complex Products Research LLC · Granted Feb 25, 2025 · Expires Feb 20, 2045

    granted

Frequently asked questions

What patents are included in this directory?

We index 1,585 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search — best for looking up a specific filing or applicant portfolio slice.